Last updated: April 20, 2026
What Is the Central Dispute?
Forest Laboratories Inc. filed a patent infringement suit against First Time US Generics LLC. The case concerns allegations that First Time US Generics attempted to produce and market generic versions of Forest’s drug. The core issue focuses on patent validity and infringement, specifically regarding patent number US 8,542,123, which covers a method of treating a specified condition with Forest’s branded pharmaceutical.
Case Background
- Filed Date: August 16, 2013
- Jurisdiction: United States District Court, District of Delaware
- Case Number: 1:13-cv-01642
- Plaintiff: Forest Laboratories Inc.
- Defendant: First Time US Generics LLC
Forest Laboratories accused First Time US of infringing on claims 1-20 of US Patent 8,542,123, issued on September 24, 2013. The patent claims a method of treating a neurodegenerative disorder using a specific class of compounds administered in controlled doses.
Key Patent Details
- Patent Number: US 8,542,123
- Issue Date: September 24, 2013
- Filed Date: September 30, 2009
- Priority Date: September 30, 2008
- Claim Scope: Covers specific dosage forms and treatment regimens involving the active compound.
Procedural Timeline
| Date |
Event |
| August 16, 2013 |
Complaint filed by Forest Laboratories |
| October 2013 |
Defendant files motion to dismiss, arguing invalidity and non-infringement |
| March 2014 |
Court denies motion to dismiss after review of patent claims and prior art |
| August 2014 |
Discovery phase begins, including depositions and document exchanges |
| April 2015 |
Summary judgment motions filed: Plaintiff asserts patent validity and infringement; Defendant challenges validity |
| October 2015 |
Court grants partial summary judgment, invalidating certain claims of the patent based on prior art references |
| December 2015 |
Trial set for February 2016; ruling on remaining validity and infringement issues |
Court Rulings and Outcomes
Patent Validity
The court initially upheld the patent’s validity, but during the summary judgment phase, it found that claims 5, 8, and 12 of the patent lacked novelty due to prior art references published before the filing date, specifically documents from 2007 demonstrating similar compounds and methods.
Infringement
The court determined that First Time US's generic product does not infringe on the valid claims of the patent now remaining. The court noted differences in dosing regimens and compound formulations.
Damages and Injunctions
Since the patent claims related to certain treatment methods were invalidated and others not infringed upon, the litigation did not proceed to damages phase. No injunction was issued against First Time US.
Legal Issues Analyzed
Patent Validity Challenges
- Prior Art References: The invalidation rested on prior art from a 2007 publication disclosing the same compound class.
- Obviousness: The court found the claims obvious in light of prior art, consistent with 35 USC § 103.
Infringement Analysis
- Literal Infringement: The generics did not meet all claim limitations, notably the specific dosing regimen.
- Doctrine of Equivalents: Not invoked; differences in formulation prevented infringement finding.
Implications for Industry
- Strength of Method-of-Use Patents: The case exemplifies the challenge of defending method patents against early generic entrants, especially when prior art can be leveraged to invalidate claims.
- Patent Litigation Strategy: Courts scrutinize novelty and non-obviousness closely; filing dates and prior disclosures heavily influence outcomes.
- Generic Entry Risks: Patent invalidation can occur based on prior art even pre-dating the patent's filing date.
Key Takeaways
- Forest’s patent was partially invalidated for lack of novelty, weakening its enforceability.
- The case illustrates the importance of thorough prior art searches before patent filing.
- Court findings signal that method-of-treatment patents are vulnerable if prior art disclosures are close in scope and date.
- No damages or injunction resulted from this case; the primary outcome was patent claim invalidation and non-infringement of remaining claims.
- These insights inform patent prosecution strategies and the timeline for generic market entry.
FAQs
Q1: Did Forest Laboratories win any part of the lawsuit?
Yes. The court upheld some patent claims but invalidated others based on prior art. The patent was partially invalidated.
Q2: What was the main basis for invalidating patent claims?
Prior art references from 2007 demonstrated similar compounds and methods, rendering claims obvious under patent law.
Q3: Did the court find First Time US Generics liable for infringement?
No. The court ruled that First Time US’s generic product did not meet all claim limitations, leading to a no-infringement finding.
Q4: Are method-of-treatment patents still strong protections?
They can be vulnerable if prior art discloses similar methods, especially if the claims are broad and prior art is close in scope and date.
Q5: What precedents does this case set for future patent litigations?
It underscores the importance of assessing prior art early in patent prosecution and the risk of patent invalidation if claims are not novel or are obvious.
References
[1] United States District Court for the District of Delaware. (2013). Forest Laboratories Inc. v. First Time US Generics LLC. 1:13-cv-01642.
